Skip to main content
Lydia Visser
PhD

My research in the Pathology department is mainly focused on immunological aspects of B-cell lymphoma. I study interactions of tumor cells with the microenvironment, and signaling pathways in Hodgkin lymphoma and non-Hodgkin lymphomas.

Programmed cell death-1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma
Published in: British Journal of Haematology
Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin Lymphoma
Published in: Blood Advances
Serum TARC dynamics during anti-PD1-based first-line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial
Published in: HemaSphere
Wouter J Plattel, Sophie Teesink, Lydia Visser, Conrad-Amadeus Voltin, Helen Kaul, Hans A Schlößer, Bart-Jan Kroesen, Carsten Kobe, Bastian von Tresckow, Peter Borchmann, Arjan Diepstra, Paul J Bröckelmann
Palmitoylation by ZDHHC family members regulate B-cell lymphoma growth
Published in: International Journal of Biological Macromolecules
The ZDHHC palmitoyl transferase family consists of 24 members, of which several have been linked to the development of cancer. We previously showed that inhibition of ZDHHC11 decreased growth of several B-cell lymphoma subtypes. In this study, we evaluated the effect of protein palmitoylation on the proteome in general and investigated expression and function of ZDHHC family members in a panel of Burkitt, Hodgkin and diffuse large B-cell lymphoma cell lines. Proteomic analysis of Burkitt lymphoma cells treated with the general palmitoylation inhibitor 2-bromopalmitate (2-BP) revealed 1089 differentially...
Yichen Liu, Shiyun Hu, Özlem Önder, Anagh Sahasrabuddhe, Ali Rajabi, Annika Seitz, Debora de Jong, Jasper Koerts, Lydia Visser, Agnieszka Dzikiewicz-Krawczyk, Megan S Lim, Kojo S Elenitoba-Johnson, Anke van den Berg, Lotteke J Y M Ziel-Swier, Joost Kluiver
HDAC10 and its implications in Sézary syndrome pathogenesis
Published in: Frontiers in Cell and Developmental Biology
Cutaneous T-cell lymphomas (CTCL) are a group of rare hematological malignancies characterized by infiltration of malignant T-cells into the skin. Two main types of CTCL constitute of Mycosis Fungoides (MF), a more indolent form of the disease, and Sézary syndrome (SS), the aggressive and leukemic variant with blood involvement. Sézary syndrome presents a significant clinical challenge due to its very aggressive nature, poor prognosis, and treatment resistance, and to date, the disease remains incurable. Histone deacetylase inhibitors have gained attention in CTCL treatment with promising results, but they...
Monika Pieniawska, Karolina Rassek, Bogumiła Skwara, Magdalena Żurawek, Iwona Ziółkowska-Suchanek, Lydia Visser, Monique Lodewijk, Małgorzata Sokołowska-Wojdyło, Berenika Olszewska, Roman J Nowicki, Tomasz Stein, Aleksandra Dańczak-Pazdrowska, Adriana Polańska, Marta Szymoniak-Lipska, Natalia Rozwadowska, Katarzyna Iżykowska